好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Clinician 好色先生 Initiatives for General Neurologists on ALS: Why It Is Needed and ThinkALS, a Possible Solution
Neuromuscular and Clinical Neurophysiology (EMG)
P5 - Poster Session 5 (5:30 PM-6:30 PM)
11-008
(a) To understand how general neurologists and other providers contribute to ALS diagnostic timelines in the U.S and (b) to develop clinician education tools for facilitating early suspicion and prompt referrals to multidisciplinary ALS centers.

Over the past 2 decades, in the US, the average time to ALS diagnosis has remained steady at 12 months, and is followed by a median survival of 18 months. These delays can result in missed or delayed opportunities for optimal care and research. ALS patients see 3-4 clinicians prior to referral to an ALS specialist for diagnosis confirmation and/or treatment initiation. There is an urgent need to identify where delays occur, so that targeted clinician awareness may be raised about benefits of early referral to multidisciplinary ALS centers.

 

(a) Retrospective review of Medicare claims database for patterns of health care utilization by ALS patients at various predefined time intervals prior to ALS diagnosis (T0). This included ambulatory care provided by general neurologists versus other physician types and (b) Annual surveys of ~75 Certified Treatment Centers of Excellence (CY2019-2021) on average wait times to new referral consultations.

During CY2011-2021, 78,520 Medicare beneficiaries were diagnosed with ALS (T0) while enrolled in the program. The mean(median) delay between first general neurologist ambulatory visit and T0, is 16.5(11.0) months. During 12 months preceding T0, an ALS patient undergoes median(max) 1.5(4.0) brain-MRIs, 1.6(6.0) spine-MRIs, and 1.3(4.0) electromyography studies.  >75% of CTCEs consistently report < 4 week wait times for new ALS patient consults. A “thinkALS” tool was developed as an easy-to-use clinical diagnostic and referral guide by iterative process and vetted by ALS experts and is being widely disseminated for routine use by non-ALS neurologists.

This study is first to provide metrics on how non-ALS/general neurologists contribute to ALS diagnostic timelines in the US.
Authors/Disclosures
Suma Babu, MD, MPH (Massachusetts General Hospital, Brigham, Harvard)
PRESENTER
The institution of Dr. Babu has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. The institution of Dr. Babu has received personal compensation in the range of $0-$499 for serving as a Consultant for Specific Biologics. The institution of Dr. Babu has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Uniqure Therapeutics. The institution of Dr. Babu has received research support from Biogen. The institution of Dr. Babu has received research support from Ionis. The institution of Dr. Babu has received research support from OrphAI therapeutics. The institution of Dr. Babu has received research support from Denali Therapeutics. The institution of Dr. Babu has received research support from Tiziana. Dr. Babu has a non-compensated relationship as a Appointed Member of the Committee on ALS: Accelerating Treatments and Improving Quality of Life with National Academies of Sciences, Engineering and Medicine that is relevant to AAN interests or activities.
Jill Yersak (Amylyx Pharmaceuticals) No disclosure on file
Ramona Krauss (ARC) No disclosure on file
Bjorn E. Oskarsson, MD, FAAN (Mayo Clinic) Dr. Oskarsson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amylyx. The institution of Dr. Oskarsson has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Oskarsson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AnnJi. The institution of Dr. Oskarsson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi. Dr. Oskarsson has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Tsumura. The institution of Dr. Oskarsson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MediciNova. The institution of Dr. Oskarsson has received research support from Biogen. The institution of Dr. Oskarsson has received research support from Medicinova. The institution of Dr. Oskarsson has received research support from Cytokinetics. The institution of Dr. Oskarsson has received research support from Calico. The institution of Dr. Oskarsson has received research support from Mitsubishi. The institution of Dr. Oskarsson has received research support from Tsumura. The institution of Dr. Oskarsson has received research support from Sanofi. The institution of Dr. Oskarsson has received research support from AZTherapeutics. The institution of Dr. Oskarsson has received research support from Orion. The institution of Dr. Oskarsson has received research support from Esaii.
Terry D. Heiman-Patterson, MD (Temple University Lewis Katz School of Medicine) Dr. Heiman-Patterson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MTPA. Dr. Heiman-Patterson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amylyx. Dr. Heiman-Patterson has received personal compensation in the range of $0-$499 for serving as a Consultant for novartis. Dr. Heiman-Patterson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for biogen. The institution of Dr. Heiman-Patterson has received research support from MTPA. The institution of Dr. Heiman-Patterson has received research support from State of Pennsylvania . The institution of Dr. Heiman-Patterson has received research support from ALS Association. The institution of Dr. Heiman-Patterson has received research support from ALS United. The institution of Dr. Heiman-Patterson has received research support from ALS Hope Foundation.
Catherine Lomen-Hoerth, MD, PhD, FAAN (UCSF) Dr. Lomen-Hoerth has nothing to disclose.
Daniel Waldo (Actuarial Research Corporation) No disclosure on file
Wendy Selig (WSCollaborative) No disclosure on file
Ilisa Paul No disclosure on file
Kuldip Dave, PhD No disclosure on file
Neil Thakur Neil Thakur has received personal compensation for serving as an employee of The ALS Association. An immediate family member of Neil Thakur has received publishing royalties from a publication relating to health care.